Berry Genomics Granted CFDA Approval for Birth Defect Test

Berry Genomics of Beijing received premarket clearance from the CFDA for the use of an Illumina NextSeq CN500 high-throughput sequencing machine and a Berry-developed non-invasive prenatal test for birth defects. The company's $500 test, which is based on circulating maternal blood serum, offers women with high-risk pregnancies greater safety than the invasive procedure. Berry said its NIPT kits have rates above 99% for both sensitivity and specificity. More details.... Stock Symbol: (NSDQ: ILMN) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.